
PHARMACEUTICAL 2018

Teligent Inc. Rank 90 of 349





PHARMACEUTICAL 2018

Teligent Inc. Rank 90 of 349

The relative strengths and weaknesses of Teligent Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Teligent Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 193% points. The greatest weakness of Teligent Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 87% points.

The company's Economic Capital Ratio, given in the ranking table, is -7.9%, being 270% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	64,532
Cost of Goods Sold	0
Intangible Assets	56,517
Liabilities, Current	24,097
Liabilities, Non-Current	0
Other Assets	582
Other Compr. Net Income	-414
Other Expenses	39,794
Other Liabilities	121,136
Other Net Income	-3,479
Property and Equipment	68,355
Research and Development	19,265
Revenues	67,251
Selling, General and Administrative Expense	19,904

Output Variable	Value in 1000 USD
Assets	189,986
Liabilities	145,233
Expenses	78,963
Stockholders Equity	44,753
Net Income	-15,191
Comprehensive Net Income	-15,398
Economic Capital Ratio	-7.9%